Which has stronger valuation & earnings, IMMX or ALXO?

Immix Biopharma is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immix Biopharma N/A N/A -$29.44M -$0.88 N/A ALX Oncology N/A N/A -$101.69M -$1.13 N/A

Is IMMX or ALXO more profitable?

Immix Biopharma's return on equity of -38.44% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -38.44% -34.72% ALX Oncology N/A -90.30% -67.28%

Does the media prefer IMMX or ALXO?

In the previous week, Immix Biopharma and Immix Biopharma both had 3 articles in the media. ALX Oncology's average media sentiment score of 0.67 beat Immix Biopharma's score of 0.41 indicating that ALX Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ACRS or ALXO?

In the previous week, Aclaris Therapeutics had 2 more articles in the media than ALX Oncology. MarketBeat recorded 5 mentions for Aclaris Therapeutics and 3 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 0.67 beat Aclaris Therapeutics' score of -0.04 indicating that ALX Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALXO or DBVT?

In the previous week, ALX Oncology and ALX Oncology both had 3 articles in the media. ALX Oncology's average media sentiment score of 0.67 beat DBV Technologies' score of -0.91 indicating that ALX Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Negative

Does the media favor ALXO or PHAR?

In the previous week, ALX Oncology had 1 more articles in the media than Pharming Group. MarketBeat recorded 3 mentions for ALX Oncology and 2 mentions for Pharming Group. ALX Oncology's average media sentiment score of 0.67 beat Pharming Group's score of 0.40 indicating that ALX Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer WVE or ALXO?

In the previous week, WAVE Life Sciences had 1 more articles in the media than ALX Oncology. MarketBeat recorded 4 mentions for WAVE Life Sciences and 3 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 0.67 beat WAVE Life Sciences' score of -0.15 indicating that ALX Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ALX Oncology (ALXO) Competitors

$1.25 +0.07 (+5.93%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.20 -0.05 (-4.00%)

As of 10/9/2026 07:30 PM Eastern

Compare

ALXO vs. IMMX, ACRS, DBVT, PHAR, and WVE

Should you buy ALX Oncology stock or one of its competitors? ALX Oncology's main competitors and comparable companies include Immix Biopharma (IMMX), Aclaris Therapeutics (ACRS), DBV Technologies (DBVT), Pharming Group (PHAR), and WAVE Life Sciences (WVE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ALX Oncology compare to Immix Biopharma?

Immix Biopharma (NASDAQ:IMMX) and ALX Oncology (NASDAQ:ALXO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

In the previous week, Immix Biopharma and Immix Biopharma both had 3 articles in the media. ALX Oncology's average media sentiment score of 0.67 beat Immix Biopharma's score of 0.41 indicating that ALX Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immix Biopharma presently has a consensus target price of $24.14, indicating a potential upside of 155.21%. ALX Oncology has a consensus target price of $4.60, indicating a potential upside of 268.00%. Given ALX Oncology's higher possible upside, analysts plainly believe ALX Oncology is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Immix Biopharma is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by company insiders. Comparatively, 12.4% of ALX Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Immix Biopharma's return on equity of -38.44% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-38.44%	-34.72%
ALX Oncology	N/A	-90.30%	-67.28%

Immix Biopharma has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market.

Summary

Immix Biopharma beats ALX Oncology on 7 of the 12 factors compared between the two stocks.

How does ALX Oncology compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and ALX Oncology (NASDAQ:ALXO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

Aclaris Therapeutics currently has a consensus price target of $11.33, suggesting a potential upside of 195.91%. ALX Oncology has a consensus price target of $4.60, suggesting a potential upside of 268.00%. Given ALX Oncology's higher probable upside, analysts clearly believe ALX Oncology is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Aclaris Therapeutics had 2 more articles in the media than ALX Oncology. MarketBeat recorded 5 mentions for Aclaris Therapeutics and 3 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 0.67 beat Aclaris Therapeutics' score of -0.04 indicating that ALX Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 98.0% of ALX Oncology shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by company insiders. Comparatively, 12.4% of ALX Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Aclaris Therapeutics has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

Aclaris Therapeutics has higher revenue and earnings than ALX Oncology. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	68.39	-$64.92M	-$0.58	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A

ALX Oncology has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -921.50%. Aclaris Therapeutics' return on equity of -61.65% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%
ALX Oncology	N/A	-90.30%	-67.28%

Summary

Aclaris Therapeutics beats ALX Oncology on 10 of the 15 factors compared between the two stocks.

How does ALX Oncology compare to DBV Technologies?

ALX Oncology (NASDAQ:ALXO) and DBV Technologies (NASDAQ:DBVT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

ALX Oncology has higher earnings, but lower revenue than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A
DBV Technologies	$5.64M	109.26	-$146.95M	-$3.51	N/A

In the previous week, ALX Oncology and ALX Oncology both had 3 articles in the media. ALX Oncology's average media sentiment score of 0.67 beat DBV Technologies' score of -0.91 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Negative

98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 12.4% of ALX Oncology shares are held by company insiders. Comparatively, 1.1% of DBV Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ALX Oncology has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -1.04, meaning that its share price is 204% less volatile than the broader market.

ALX Oncology currently has a consensus target price of $4.60, suggesting a potential upside of 268.00%. DBV Technologies has a consensus target price of $48.50, suggesting a potential upside of 394.90%. Given DBV Technologies' higher probable upside, analysts plainly believe DBV Technologies is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
DBV Technologies	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

ALX Oncology has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. ALX Oncology's return on equity of -90.30% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-90.30%	-67.28%
DBV Technologies	-3,506.53%	-119.33%	-84.43%

Summary

ALX Oncology beats DBV Technologies on 10 of the 12 factors compared between the two stocks.

How does ALX Oncology compare to Pharming Group?

ALX Oncology (NASDAQ:ALXO) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

ALX Oncology has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Pharming Group has a beta of -0.05, indicating that its share price is 105% less volatile than the broader market.

Pharming Group has a net margin of 2.51% compared to ALX Oncology's net margin of 0.00%. Pharming Group's return on equity of 3.40% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-90.30%	-67.28%
Pharming Group	2.51%	3.40%	1.90%

Pharming Group has higher revenue and earnings than ALX Oncology. ALX Oncology is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A
Pharming Group	$366.48M	1.89	$2.85M	$0.12	81.58

In the previous week, ALX Oncology had 1 more articles in the media than Pharming Group. MarketBeat recorded 3 mentions for ALX Oncology and 2 mentions for Pharming Group. ALX Oncology's average media sentiment score of 0.67 beat Pharming Group's score of 0.40 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 12.4% of ALX Oncology shares are held by company insiders. Comparatively, 2.1% of Pharming Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ALX Oncology currently has a consensus target price of $4.60, indicating a potential upside of 268.00%. Pharming Group has a consensus target price of $38.67, indicating a potential upside of 294.96%. Given Pharming Group's higher probable upside, analysts plainly believe Pharming Group is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Pharming Group beats ALX Oncology on 8 of the 15 factors compared between the two stocks.

How does ALX Oncology compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and ALX Oncology (NASDAQ:ALXO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

89.7% of WAVE Life Sciences shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 24.3% of WAVE Life Sciences shares are owned by insiders. Comparatively, 12.4% of ALX Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

WAVE Life Sciences presently has a consensus target price of $21.65, indicating a potential upside of 525.64%. ALX Oncology has a consensus target price of $4.60, indicating a potential upside of 268.00%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

ALX Oncology has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -309.73%. WAVE Life Sciences' return on equity of -50.36% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-309.73%	-50.36%	-40.06%
ALX Oncology	N/A	-90.30%	-67.28%

ALX Oncology has lower revenue, but higher earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	15.96	-$204.38M	-$1.09	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A

In the previous week, WAVE Life Sciences had 1 more articles in the media than ALX Oncology. MarketBeat recorded 4 mentions for WAVE Life Sciences and 3 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 0.67 beat WAVE Life Sciences' score of -0.15 indicating that ALX Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

WAVE Life Sciences has a beta of -1.43, meaning that its stock price is 243% less volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

Summary

WAVE Life Sciences beats ALX Oncology on 9 of the 15 factors compared between the two stocks.

Get ALX Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALXO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALXO vs. The Competition

Export

Metric	ALX Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$163.17M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-1.11	13.42	274.15	26.16
Price / Sales	N/A	1,234.38	635.98	112.53
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	2.60	17.17	11.21	6.34
Net Income	-$101.69M	-$22.69M	$3.50B	$381.90M
7 Day Performance	2.46%	-1.33%	-0.90%	-1.41%
1 Month Performance	-34.21%	-8.44%	-4.44%	-3.48%
1 Year Performance	-23.78%	14.02%	6.96%	1.16%

ALX Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALXO ALX Oncology	3.2948 of 5 stars	$1.25 +5.9%	$4.60 +268.0%	-35.6%	$163.17M	N/A	N/A	48
IMMX Immix Biopharma	2.893 of 5 stars	$10.30 -10.2%	$22.86 +121.9%	+266.7%	$737.43M	N/A	N/A	21
ACRS Aclaris Therapeutics	1.9391 of 5 stars	$5.27 -3.0%	$11.33 +115.3%	+96.4%	$736.15M	$7.83M	N/A	73	News Coverage
DBVT DBV Technologies	3.4091 of 5 stars	$11.56 -0.7%	$48.50 +319.7%	-38.2%	$722.81M	$5.64M	N/A	161
PHAR Pharming Group	4.1997 of 5 stars	$10.15 -3.5%	$38.67 +281.0%	-32.9%	$718.35M	$376.13M	84.58	407

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALXO) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ALX Oncology (ALXO) Competitors

ALXO vs. IMMX, ACRS, DBVT, PHAR, and WVE

How does ALX Oncology compare to Immix Biopharma?

Summary

How does ALX Oncology compare to Aclaris Therapeutics?

Summary

How does ALX Oncology compare to DBV Technologies?

Summary

How does ALX Oncology compare to Pharming Group?

Summary

How does ALX Oncology compare to WAVE Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO vs. The Competition

ALX Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ALX Oncology (ALXO) Competitors

ALXO vs. IMMX, ACRS, DBVT, PHAR, and WVE

How does ALX Oncology compare to Immix Biopharma?

Does the media prefer IMMX or ALXO?

Do analysts rate IMMX or ALXO?

Which has stronger valuation & earnings, IMMX or ALXO?

Do institutionals & insiders believe in IMMX or ALXO?

Is IMMX or ALXO more profitable?

Which has more volatility & risk, IMMX or ALXO?

Summary

How does ALX Oncology compare to Aclaris Therapeutics?

Do analysts recommend ACRS or ALXO?

Does the media refer more to ACRS or ALXO?

Do institutionals & insiders hold more shares of ACRS or ALXO?

Which has more risk & volatility, ACRS or ALXO?

Which has better valuation and earnings, ACRS or ALXO?

Is ACRS or ALXO more profitable?

Summary

How does ALX Oncology compare to DBV Technologies?

Which has stronger valuation and earnings, ALXO or DBVT?

Does the media favor ALXO or DBVT?

Do institutionals and insiders have more ownership in ALXO or DBVT?

Which has more volatility & risk, ALXO or DBVT?

Do analysts recommend ALXO or DBVT?

Is ALXO or DBVT more profitable?

Summary

How does ALX Oncology compare to Pharming Group?

Which has more risk & volatility, ALXO or PHAR?

Is ALXO or PHAR more profitable?

Which has higher valuation and earnings, ALXO or PHAR?

Does the media favor ALXO or PHAR?

Do institutionals & insiders believe in ALXO or PHAR?

Do analysts recommend ALXO or PHAR?

Summary

How does ALX Oncology compare to WAVE Life Sciences?

Do insiders and institutionals believe in WVE or ALXO?

Do analysts rate WVE or ALXO?

Is WVE or ALXO more profitable?

Which has better earnings & valuation, WVE or ALXO?

Does the media prefer WVE or ALXO?

Which has more risk & volatility, WVE or ALXO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO vs. The Competition

ALX Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools